Filing Details

Accession Number:
0001104659-20-012712
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-07 20:08:59
Reporting Period:
2020-02-05
Accepted Time:
2020-02-07 20:08:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1297184 Amphastar Pharmaceuticals Inc. AMPH Pharmaceutical Preparations (2834) 330702205
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1611148 B. Jason Shandell C/O Amphastar Pharmaceuticals, Inc.
11570 6Th Street
Rancho Cucamonga CA 91730
President And General Counsel Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-05 15,615 $14.40 154,513 No 4 M Direct
Common Stock Disposition 2020-02-05 15,615 $19.57 138,898 No 4 S Direct
Common Stock Acquisiton 2020-02-06 21,933 $14.40 160,831 No 4 M Direct
Common Stock Disposition 2020-02-06 21,933 $19.83 138,898 No 4 S Direct
Common Stock Acquisiton 2020-02-07 6,853 $14.40 145,751 No 4 M Direct
Common Stock Disposition 2020-02-07 6,853 $19.88 138,898 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-02-05 15,615 $0.00 15,615 $14.40
Common Stock Employee Stock Option (right to buy) Disposition 2020-02-06 21,933 $0.00 21,933 $14.40
Common Stock Employee Stock Option (right to buy) Disposition 2020-02-07 6,853 $0.00 6,853 $14.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,730 2024-03-27 No 4 M Direct
53,797 2024-03-27 No 4 M Direct
46,944 2024-03-27 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.35 to $19.77 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
  3. The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $19.58 to $19.99, inclusive.
  4. The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive.
  5. Shares subject to the option are fully vested and immediately exercisable.